These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Benzinga

Aug 14

Altimmune, Inc. (NASDAQ:ALT) posted a loss for the second quarter on Tuesday.

The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.

“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”

Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.

These analysts made changes to their price targets on Altimmune following earnings announcement.

B. Riley Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.
UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.
HC Wainwright & Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.

Considering buying ALT stock? Here’s what analysts think:

Read This Next:

Top 2 Tech & Telecom Stocks That May Fall Off A Cliff In Q3

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2559986600"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559986600\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559986600?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 02:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559986600","market":"us","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On Altimmune Following Q2 Results","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a></strong> (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.</p>\n<p>“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”</p>\n<p>Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Altimmune following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/RILY\">B. Riley</a> Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.</li>\n<li>UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.</li>\n<li>HC Wainwright &amp; Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.</li>\n</ul>\n<p><strong>Considering buying ALT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"575\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238.png 1108w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Tech &amp; Telecom Stocks That May Fall Off A Cliff In Q3</strong></li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On Altimmune Following Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On Altimmune Following Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-08-14 02:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a></strong> (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.</p>\n<p>“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”</p>\n<p>Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Altimmune following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/RILY\">B. Riley</a> Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.</li>\n<li>UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.</li>\n<li>HC Wainwright &amp; Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.</li>\n</ul>\n<p><strong>Considering buying ALT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"575\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238.png 1108w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Tech &amp; Telecom Stocks That May Fall Off A Cliff In Q3</strong></li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/47103330/these-analysts-slash-their-forecasts-on-altimmune-following-q2-results","article_id":"2559986600","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559986600","pubTimestamp":1755111443,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","ALT":"Altimmune, Inc.","BK4599":"减肥药"},"translate_title":"这些分析师在第二季度业绩公布后大幅下调了对Altimmune的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"Altimmune, Inc. (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.\nThe company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.\n“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”\nAltimmune shares gained 5.7% to trade at $3.8250 on Wednesday.\nThese analysts made changes to their price targets on Altimmune following earnings announcement.\n\nB. Riley Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.\nUBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.\nHC Wainwright & Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.\n\nConsidering buying ALT stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 2 Tech & Telecom Stocks That May Fall Off A Cliff In Q3\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}